Glofitamab With Gemcitabine/Oxaliplatin Improves Survival in Transplant-Ineligible R/R DLBCL
June 15th 2024Data from STARGLO showed that fixed-duration glofitamab-gxbm (Columvi) plus gemcitabine/oxaliplatin significantly improved survival compared with rituximab (Rituxan) plus gemcitabine/oxaliplatin in select patients with relapsed/refractory diffuse large B-cell lymphoma.
Efficacy Improvement Noted in Abemaciclib Regimen in HR+/HER2- Breast Cancer
June 2nd 2024Increased PFS was noted with abemaciclib plus fulvestrant vs fulvestrant alone in hormone receptor–positive, HER2-negative advanced breast cancer after disease progression on a CDK4/6 inhibitor and endocrine therapy.